In the present study, we found that the serum IL8 level in pancreatic cancer patients with resistance to platinum-based chemotherapy was higher than that in chemosensitive patients, and that the administration of platinum-based adjuvant chemotherapy resulted in more significant differences in the IL8 level between the two groups of patients. This evidence concerns the gene CXCL8 and familial pancreatic carcinoma.